Major Investment for Psychiatric Drug Development
Co-founders Dr Greg Stewart, Associate Professor Jess Nithianantharajah and Professor Chris Langmead TIA’s Pipeline Accelerator Helps Phrenix Therapeutics Secure Major Investment for Psychiatric Drug Development Phrenix Therapeutics, a biotech company developing next-generation medicines for psychiatric and neurological disorders, has secured seed investment from Curie.Bio (US) and Brandon Capital (Australia). Therapeutic Innovation Australia (TIA) is proud to […]
Australian Translational Medicinal Chemistry Facility
The Australian Translational Medicinal Chemistry Facility (ATMCF) is a purpose-designed and outward-facing collaborative facility, translating new discoveries in disease biology into suitably targeted therapeutics for clinical development. ATMCF partners with suitable researchers and companies to efficiently and effectively address the multifaceted requirements of drug-discovery. Read more about ATMCF here
Centre for Drug Candidate Optimisation
The Centre for Drug Candidate Optimisation (CDCO) is a collaborative research centre based within the Monash Institute of Pharmaceutical Sciences. CDCO provides expertise and infrastructure in physicochemical property evaluation, drug metabolism and pharmacokinetics to multidisciplinary drug discovery teams for improved compound design, selection and progression. Read more about CDCO here